PALO ALTO, Calif., July 27 /PRNewswire-FirstCall/ -- Telik, Inc. announced that its quarterly conference call and webcast will be held on Thursday, August 3, 2006 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release of Telik’s financial results for the second quarter and six months ended June 30, 2006 earlier that day.
The conference call will be accessible via Telik’s website at www.telik.com or by telephone at 800-230-1085 or 612-288-0329. An archive of the conference call will be available on the Telik website from approximately 8:30 p.m. Eastern time on August 3 through August 10, 2006, or by telephone at 800-475-6701 or 320-365-3844, access code 837921.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA(R) (TLK286), a tumor-activated small molecule product candidate which is in four Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, Inc., +1-650-845-7728, or cdeguzman@telik.com
Web site: http://www.telik.com/
